Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients *

No abstract is available for this paper.

• Publication year

  2007

• Venue

  HIV Medicine

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-1293.2007.00442.xPMID 17352770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atazanavir

  2012cited by this paper
• Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers

  2006cited by this paper
• Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.

  2005cited by this paper
• Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

  2004cited by this paper
• 6th International Workshop on Clinical Pharmacology of HIV Therapy

  2004cited by this paper
• Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy

  2002cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin

  2002cited by this paper
• Rifampin and rifabutin drug interactions: an update.

  2002cited by this paper
• Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis

  2002cited by this paper
• Administration of Indinavir and Low-Dose Ritonavir (800/100 Mg Twice Daily) with Food Reduces Nephrotoxic Peak Plasma Levels of Indinavir

  2002cited by this paper
• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  2001cited by this paper
• AIDS across Europe, 1994-98: the EuroSIDA study.

  2000cited by this paper
• Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

  2000cited by this paper
• Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

  1999cited by this paper
• Ritonavir enables combined therapy with rifampin and saquinavir.

  1999cited by this paper
• The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

  1999cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

  1996cited by this paper
• Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

  1992cited by this paper

• Potential drug–drug interactions of frequently prescribed medications in long COVID detected by two electronic databases

  2023cites this paper
• From bedside to bench and back : future options for antiretroviral drugs in non-B HIV-1 subtypes

  2020cites this paper
• Reducing the tuberculosis burden in migrant populations through latent tuberculosis infection interventions : a series of cost-effectiveness analyses

  2018cites this paper
• Addressing Antiretroviral Therapy‐Associated Drug‐Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low‐Income and Resource‐Limited Settings

  2017cites this paper
• Addressing Antiretroviral TherapyAssociated DrugDrug Interactions in Patients Requiring Treatment for Opportunistic Infections in LowIncome and ResourceLimited Settings

  2017cites this paper
• Investigational protease inhibitors as antiretroviral therapies

  2016cites this paper
• Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

  2016cites this paper
• Predicting Rat and Human Pregnane X Receptor Activators Using Bayesian Classification Models.

  2016cites this paper
• Drugs used in tuberculosis and leprosy

  2014cites this paper
• Human Immunodeficiency Virus and Tuberculosis Co-Infection

  2014cites this paper
• Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis

  2013cites this paper
• Pharmacokinetic targets of antiretroviral therapy in children and adolescents

  2013cites this paper
• Management of tuberculosis in HIV-infected patients.

  2012cites this paper
• Influence of Rifampicin on the Pharmacokinetics of Salvianolic Acid B May Involve Inhibition of Organic Anion Transporting Polypeptide (Oatp) Mediated Influx

  2012cites this paper
• Pharmacokinetics and 48 Week Efficacy of Adjusted Dose Indinavir/Ritonavir in Rifampicin-Treated HIV/Tuberculosis-Coinfected Patients: A Pilot Study

  2012cites this paper
• Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

  2012cites this paper
• Interactions of antiretroviral protease inhibitors with hepatic transport proteins: Mechanisms of drug-induced liver injury

  2012cites this paper
• Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

  2011cites this paper
• British HIV Association guidelines for the treatment of TB / HIV coinfection 2010

  2011cites this paper
• British HIV Association guidelines for the treatment of TB/HIV coinfection 2011

  2011cites this paper
• Rifamycin Use in HIV-Infected Patients with Tuberculosis

  2011cites this paper
• Initiating antiretrovirals during tuberculosis treatment: a drug safety review

  2011cites this paper
• Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART

  2011cites this paper
• Interaction Potential of Etravirine with Drug Transporters Assessed In Vitro

  2010cites this paper
• [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)].

  2010cites this paper
• Running title: Management of HIV-1-TB

  2010cites this paper
• Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline *

  2010cites this paper
• Antiviral drugs

  2010cites this paper
• Clinical management of tuberculosis and HIV-1 co-infection

  2010cites this paper
• Rifampin Combination Therapy for Nonmycobacterial Infections

  2010cites this paper
• Clinical pharmacology, efficacy and safety of atazanavir: a review

  2009cites this paper
• Clinicalpharmacology,efficacy andsafetyofatazanavir:areview

  2009cites this paper
• Toxicity of HIV protease inhibitors: clinical considerations

  2008cites this paper
• HIV and TB in industrialized countries

  2008cites this paper
• Farmacología, aspectos farmacocinéticos e interacciones de atazanavir

  2008cites this paper
• Atazanavir/ritonavir: a review of its use in HIV therapy.

  2008cites this paper
• Interactions between antiretroviral agents and those used to treat tuberculosis

  2008cites this paper
• [Pharmacology, pharmacokinetic features and interactions of atazanavir].

  2008cites this paper
• Concurrent drug therapy for tuberculosis and HIV infection in resource-limited settings: present status and future prospects

  2007cites this paper
• Optimal Timing and Best Antiretroviral Regimen in Treatment-naive HIV-Infected Individuals with Advanced Disease

  2007cites this paper